|
1
|
Li Y, Yan B and He S: Advances and
challenges in the treatment of lung cancer. Biomed Pharmacother.
169:1158912023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gao S, Li N, Wang S, Zhang F, Wei W, Li N,
Bi N, Wang Z and He J: Lung Cancer in People's Republic of China. J
Thorac Oncol. 15:1567–1576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cufer T, Ovcaricek T and O'Brien ME:
Systemic therapy of advanced non-small cell lung cancer:
Major-developments of the last 5-years. Eur J Cancer. 49:1216–1225.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kader YA, Le Chevalier T, El-Nahas T and
Sakr A: Comparative study analyzing survival and safety of
bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in
chemotherapy-naive patients with advanced non-squamous bronchogenic
carcinoma not harboring EGFR mutation. Onco Targets Ther.
6:803–809. 2013.PubMed/NCBI
|
|
8
|
Chen P, Liu Y, Wen Y and Zhou C: Non-small
cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaur J, Elms J, Munn AL, Good D and Wei
MQ: Immunotherapy for non-small cell lung cancer (NSCLC), as a
stand-alone and in combination therapy. Crit Rev Oncol Hematol.
164:1034172021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim H and Chung JH: PD-L1 testing in
non-small cell lung cancer: Past, present, and future. J Pathol
Transl Med. 53:199–206. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramagopal UA, Liu W, Garrett-Thomson SC,
Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S,
Rangan VS, et al: Structural basis for cancer immunotherapy by the
first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci
USA. 114:E4223–E4232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Updated Analysis of KEYNOTE-024: Pembrolizumab versus
platinum-based chemotherapy for advanced non-small-cell lung cancer
with PD-L1 tumor proportion score of 50% or Greater. J Clin Oncol.
37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro GJ Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jassem J, de Marinis F, Giaccone G,
Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC,
Andric Z, et al: Updated Overall Survival Analysis From IMpower110:
Atezolizumab versus platinum-based chemotherapy in treatment-naive
programmed death-ligand 1-Selected NSCLC. J Thorac Oncol.
16:1872–1882. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han
B, Cang S, Chen G, Mei X, Yang Z, et al: Updated overall survival
data and predictive biomarkers of sintilimab plus pemetrexed and
platinum as first-line treatment for locally advanced or metastatic
nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol.
16:2109–2120. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, Mcfadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hwang JK, Page BJ, Flynn D, Passmore L,
Mccau E, Brady J, Yang IA, Marshall H, Windsor M, Bowman RV, et al:
Validation of the Eighth Edition TNM Lung Cancer Staging System. J
Thorac Oncol. 15:649–654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsao MS, Kerr KM, Kockx M, Beasley MB,
Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, et
al: PD-L1 Immunohistochemistry comparability study in real-life
clinical samples: Results of blueprint phase 2 project. J Thorac
Oncol. 13:1302–1311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gadgeel S, Rodriguez-Abreu D, Speranza G,
Esteban E, Felip E, Domine M, Hui R, Hochmair MJ, Clingan P, Powell
SF, et al: Updated Analysis From KEYNOTE-189: Pembrolizumab or
placebo plus pemetrexed and platinum for previously untreated
metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol.
38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok
T, Zhang L, Tu HY, Wu L, Feng J, et al: Nivolumab versus docetaxel
in a predominantly chinese patient population with previously
treated advanced NSCLC: CheckMate 078 randomized phase III clinical
trial. J Thorac Oncol. 14:867–875. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L,
Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab plus
carboplatin and pemetrexed versus chemotherapy alone in
chemotherapy-naive patients with advanced non-squamous
non-small-cell lung cancer (CameL): A randomised, open-label,
multicentre, phase 3 trial. Lancet Respir Med. 9:305–314. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma
Z, Li X, Zhuang W, Liu Y, et al: Tislelizumab plus chemotherapy as
first-line treatment for locally advanced or metastatic nonsquamous
NSCLC (RATIONALE 304): A Randomized phase 3 trial. J Thorac Oncol.
16:1512–1522. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Negrao MV, Skoulidis F, Montesion M,
Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, et al:
Oncogene-specific differences in tumor mutational burden, PD-L1
expression, and outcomes from immunotherapy in non-small cell lung
cancer. J Immunother Cancer. 9:e0028912021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horn L, Spigel DR, Vokes EE, Holgado E,
Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L,
et al: Nivolumab versus docetaxel in previously treated patients
with advanced non-small-cell lung cancer: Two-Year outcomes from
two Randomized, open-label, phase III trials (CheckMate 017 and
CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Borghaei H, Gettinger S, Vokes EE, Chow
LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O,
Frontera OA, Chiari R, et al: Five-Year outcomes from the
Randomized, phase III Trials CheckMate 017 and 057: Nivolumab
versus docetaxel in previously treated non–small-cell lung cancer.
J Clin Oncol. 39:723–733. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
West H, Mccleod M, Hussein M, Morabito A,
Rittmeyer A, Conter HJ, Kopp HG, Daniel D, Mccune S, Mekhail T, et
al: Atezolizumab in combination with carboplatin plus
nab-paclitaxel chemotherapy compared with chemotherapy alone as
first-line treatment for metastatic non-squamous non-small-cell
lung cancer (IMpower130): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:924–937. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Waterhouse D, Lam J, Betts KA, Yin L, Gao
S, Yuan Y, Hartman J, Rao S, Lubinga S and Stenehjem D: Real-world
outcomes of immunotherapy-based regimens in first-line advanced
non-small cell lung cancer. Lung Cancer. 156:41–49. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishio M, Barlesi F, West H, Ball S,
Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S,
Orlandi F, et al: Atezolizumab plus chemotherapy for first-line
treatment of nonsquamous NSCLC: Results from the Randomized phase 3
IMpower132 Trial. J Thorac Oncol. 16:653–664. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tournoy KG, Thomeer M, Germonpre P,
Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E,
Schildermans R, Declercq I, et al: Does nivolumab for progressed
metastatic lung cancer fulfill its promises? An efficacy and safety
analysis in 20 general hospitals. Lung Cancer. 115:49–55. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Funazo T, Nomizo T and Kim YH: Liver
metastasis is associated with poor progression-free survival in
patients with non-small cell lung cancer treated with nivolumab. J
Thorac Oncol. 12:e140–e141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikeuchi N, Igata F, Kinoshita E, Kawabata
T, Tan I, Osaki Y, Otsuka R, On R, Ikeda T, Nakao A, et al:
Real-world efficacy and safety of atezolizumab plus bevacizumab,
paclitaxel and carboplatin for first-line treatment of Japanese
patients with metastatic non-squamous non-small cell lung cancer.
Anticancer Res. 43:713–724. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng L, Xiong A, Wang S, Xu J, Shen Y,
Zhong R, Lu J, Chu T, Zhang W, Li Y, et al: Decreased
monocyte-to-lymphocyte ratio was associated with satisfied outcomes
of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV
non-small cell lung cancer. Front Immunol. 14:10943782023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gu X, Shi Z, Shao L, Zhang Y, Zhang Y,
Song Z, Wang W and Lou G: Efficacy and safety of maintenance immune
checkpoint inhibitors with or without pemetrexed in advanced
non-squamous non-small cell lung cancer: A retrospective study. BMC
Cancer. 22:5762022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perol M, Felip E, Dafni U, Polito L, Pal
N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R and Peters S:
Effectiveness of PD-(L)1 inhibitors alone or in combination with
platinum-doublet chemotherapy in first-line (1L) non-squamous
non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression
using real-world data. Ann Oncol. 33:511–521. 2022. View Article : Google Scholar : PubMed/NCBI
|
